SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Spare tire got you feeling deflated? A functional medicine specialist says a hormonal imbalance could be to blame for your ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

GLP-1RA prescription trends, real-world effectiveness, and predictors for access and rationing were highlighted at ...

The following is a summary of “Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized ...

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Lexaria Bioscience (LEXX) has engaged a contract research organization to perform the world’s first-ever fluorescently tagged ...